Cancer Data on CTIC Candidate - Zacks.com
Cancer Data on CTIC CandidateZacks.comRecently, Cell Therapeutics, Inc. (CTIC - Analyst Report) announced that data from a phase I/II study which evaluated its cancer candidate pixantrone as a combination therapy was published in a medical journal, Leukemia %26 lymphoma. ...Cell Therapeutics Says Experimental lymphoma Drug Offers High Response RateRTT NewsTop Nasdaq Stock %26ndash; Cell Therapeutics Shares jump after Clinical Trial DataBeacon Equity ResearchWritten by TradersHuddle StaffTradersHuddle.comall 13 news articles��
Blog Content
Post a Comment